A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19

Authors:

Dr Fasihul Khan. Respiratory Medicine, University of Nottingham, Clinical Sciences Building,

Nottingham City Hospital, Hucknall Road, Nottingham, UK

Dr Iain Stewart. Respiratory Medicine, University of Nottingham, Clinical Sciences Building,

Nottingham City Hospital, Hucknall Road, Nottingham, UK

Dr Laura Fabbri. Respiratory Medicine, University of Nottingham, Clinical Sciences Building,

Nottingham City Hospital, Hucknall Road, Nottingham, UK

Samuel Moss, Respiratory Medicine, University of Nottingham, Clinical Sciences Building,

Nottingham City Hospital, Hucknall Road, Nottingham, UK

Professor Karen A. Robinson. John Hopkins University

Professor Alan Smyth. Division of Child Health, Obstetrics & Gynaecology, University of

Nottingham, Nottingham, UK

Professor Gisli Jenkins. Respiratory Medicine, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK

Correspondence to:

Dr Fasihul Khan fasihul.khan@nottingham.ac.uk

Total word count: 3494 Abstract word count: 250

PROSPERO registration number: CRD42020176375

Date of registration: 25th March 2020

ABSTRACT

Background

There is accumulating evidence for an overly activated immune response in severe Covid-19, with several studies exploring the therapeutic role of immunomodulation. Through systematic review and meta-analysis, we assess the effectiveness of specific interleukin inhibitors for the treatment of Covid-19.

Methods

Electronic databases were searched on 7th January 2021 to identify studies of immunomodulatory agents (anakinra, sarilumab, siltuximab and tocilizumab) for the treatment of Covid-19. The primary outcomes were severity on an ordinal scale measured at day 15 from intervention and days to hospital discharge. Key secondary endpoints included overall mortality.

Results

71 studies totalling 22,058 patients were included, six were randomised trials. Most explored outcomes in patients who received tocilizumab (59/71). In prospective studies, tocilizumab was associated with improved unadjusted survival (RR 0.83 95%CI 0.72;0.96 $I^2 =$ 0.0%), but conclusive benefit was not demonstrated for other outcomes. In retrospective studies, tocilizumab was associated with less severe outcomes on an ordinal scale (Generalised odds ratio 1.34 95%Cl 1.10;1.64, I^2 =98%) and adjusted mortality risk (HR 0.54

95%CI 0.40;0.72, I^2 =86.6%). The mean difference in duration of hospitalisation was 0.36 days (95%CI -0.07;0.80, I^2 =93.8%). There was substantial heterogeneity in retrospective studies, and estimates should be interpreted cautiously. Other immunomodulatory agents showed similar effects to tocilizumab, but insufficient data precluded meta-analysis by agent.

Conclusion

Tocilizumab was associated with a lower relative risk of mortality in prospective studies, but effects were inconclusive for other outcomes. Current evidence for the efficacy of anakinra, siltuximab or sarilumab in Covid-19 is insufficient, with further studies urgently needed for conclusive findings.

INTRODUCTION

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan, China in December 2019(1). Since then, coronavirus disease 2019 (Covid-19) has been declared a global pandemic by the World Health Organisation (WHO) and continues to spread at an exponential rate with almost two million deaths reported worldwide (2, 3).

The clinical manifestations of Covid-19 tend to be heterogenous ranging from asymptomatic infection to acute respiratory disease syndrome (ARDS), multi-organ failure and death. Mechanisms underlying severe disease are incompletely understood, but accumulating evidence points towards a dysregulated and excessive host immune response referred to as cytokine storm syndrome (CSS)(4). During this state of immunological hyperactivation, increased circulating levels of pro-inflammatory cytokines including interleukin (IL)-1 and IL-6 have been demonstrated, and are associated with adverse clinical outcomes (5-7). Suppression of pro-inflammatory cytokines in Covid-19 may therefore be a potential therapeutic strategy (8).

SARS-CoV-2 shares a number of genetic and clinical similarities with other zoonotic coronaviruses, including severe acute respiratory syndrome coronavirus (SARS) and Middle East respiratory syndrome (MERS)(9, 10). There are also reports of elevated proinflammatory cytokines in patients with SARS and MERS (11, 12), suggesting overlapping therapeutic targets in the management of SARS, MERS and Covid-19.

Several clinical studies evaluating the role of immunomodulatory agents in Covid-19 have been published recently. Through systematic review and critical appraisal of the literature, we assess the effectiveness and safety of specific IL-1 (anakinra) and IL-6 (tocilizumab, siltuximab, sarilumab) inhibitors for the treatment of Covid-19, drawing on literature from previous similar coronavirus infections (SARS and MERS) where available. These agents already carry approval for the treatment of other rare non-infectious and autoimmune conditions, with an acceptable safety profile.

METHODS

The systematic review was conducted in accordance with a pre-specified protocol (PROSPERO registration number: CRD42020176375), and has been reported in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines(13).

Search strategy and study selection

Electronic database searches were carried out in MEDLINE (1946 to latest) and EMBASE (1974 to latest), and ongoing clinical trial registries (clinicaltrials.gov and EU Clinical Trials Register), with the last search carried out on 7th January 2021. Search terms were broad and included keywords and controlled vocabulary for patient and treatment-related terms (Figure S1 for MEDLINE search strategy). Unpublished and ongoing studies were identified by searching pre-print servers including medRxiv and bioRxiv. Searches were carried out independently by two reviewers in a standardised manner, followed by screening through

titles and abstracts, before full text review. Disagreements were resolved by consensus, with unresolved conflicts decided by a third reviewer.

The review included all original studies excluding case reports, evaluating the use of at least one of anakinra, tocilizumab, sarilumab or siltuximab in patients aged over 18 with either suspected or confirmed Covid-19, SARS or MERS. Retrospective studies without a comparator arm were excluded due to their associated heterogeneity and inherent risk of bias. Language or year of publication restrictions were not applied. No minimal study sample size was specified for inclusion.

The planned primary outcomes were selected based on their clinical usefulness and included time to hospital discharge (days) and severity on an adapted four-point ordinal scale at day 15 following intervention, with the following ratings: i) death; ii) requirement for invasive mechanical ventilation (IMV) or Extra Corporal Membrane Oxygenation (ECMO); iii) hospitalised but no requirement for IMV/ECMO; iv) not hospitalised. Secondary outcomes included time to clinical improvement (days), duration of mechanical ventilation (days), overall mortality, mortality at 28 days and treatment related adverse events. For all outcomes studied, baseline was defined as the day of intervention.

Data extraction and risk of bias assessment

Data were extracted from article text and figures using a data-extraction proforma and verified by a second reviewer. Information sought included study design, sample size, participant demographics, clinical investigation findings, intervention characteristics (name

of agent, dose, route), treatment related adverse events, requirement and duration of invasive and non-invasive ventilation, use and dosage of oxygen, duration of hospital stay, survival outcome measures and follow up duration. Where ordinal outcomes were reported at multiple timepoints, those closest to day 15 post intervention were chosen for extraction. For ongoing trial protocols, the registration number, sample size, and expected date of completion were recorded.

Risk of bias assessment was carried out independently in duplicate. Due to the heterogeneity of study designs, various quality assessment tools available through the National Institute of Health were applied(14). The tools assess risk of bias through criterion specific to each study design, before providing an overall quality rating of good, fair or poor. Randomised studies were assessed using the Cochrane risk-of-bias tool for randomised trials (RoB2)(15). As per the review protocol, all studies were included irrespective of their risk of bias rating. Using the GRADE approach, we rated the overall quality of evidence for each outcome as high, moderate, low or very low(16).

Statistical analysis

All identified studies were included in the narrative summary with summary tables for characteristics. For the primary outcomes, numbers of individuals meeting each outcome on the adapted ordinal scale were pooled using rank-based Wilcoxon Mann Whitney tests with ties split evenly between positive and negative outcomes, providing a generalised odds ratio (GenOR) with 95% confidence intervals (CI). The GenOR provides a measure of the

likelihood that the intervention leads to a better rather than worse outcome when compared to a randomly chosen control (17). Mean hospital duration and standard deviation (SD) were extracted or were estimated from median and range/interquartile range (IQR) using the Box-Cox method (18). Mean difference in hospital stay was calculated where a control arm was reported. Where available, adjusted hazard ratios (HR) and unadjusted mortality data were extracted for quantitative synthesis. Where data were not reported in a tabular format, values were extracted from plotted data using a digital plot analyser(19).

Where sufficient studies were identified for a specific immunomodulator, findings were assessed using random effects meta-analysis and presented as forest plots. Meta-analyses were grouped by retrospective and prospective design and presented on the same plots with no overall estimate. The I² statistic was used to evaluate statistical heterogeneity. Although sample sizes were limited, we used pseudo-R² from meta-regression to explore variability in heterogeneity owing to study design (single-centre or multicentre), non-peer reviewed manuscripts, concomitant use of steroids, route of drug administration (intravenous or subcutaneous), and day outcome measured. Publication bias was assessed using funnel plot analysis and Egger's test. Prospective studies without a control arm were excluded from meta-analysis and presented either in the narrative summary or in tables. All analyses were performed using Stata v.16 (StataCorp, College Station, TX, USA).

RESULTS

Search of the electronic databases (MEDLINE and EMBASE) on 7th January 2021 yielded a total of 2585 studies, with a further 576 studies identified through preprint servers. Following removal of duplicates, screening and full text review, 71 articles published worldwide were shortlisted for inclusion (anakinra, n=6; tocilizumab, n=58; anakinra and tocilizumab, n=1; sarilumab and tocilizumab, n=1; sarilumab, n=4; siltuximab, n=1) (Figure 1). Sixty-two studies were published in peer-reviewed journals, with the remaining nine identified through preprint servers. All studies were performed in patients with Covid-19, with no suitable studies identified for SARS or MERS. Twenty-nine studies were prospective in design, with seventeen studies including a control group for comparison, of which six were randomised studies. The remaining 42 studies were retrospective studies with control arms. Included studies provided a total of 22,058 patients, of which 7328 (33%) received one of the therapies under review alongside standard of care (SOC), and 14730 (67%) received SOC alone. Individual study characteristics for the published studies are presented in Tables 1 and 2 (and Tables S1-S2)

Risk of bias assessment of the retrieved studies identified multiple limitations and highlighted a number of biases (Figure 2 and Table S3). The majority of included studies defined the study population specifically with clear inclusion/exclusion criteria. Where applicable, control participants were selected from the same population. However, many studies provided insufficient detail of the interventions and outcomes being studied or reporting was inconsistent, with key design, and outcome details omitted. Statistical analysis was variably reported, with few studies providing a sample size justification. In nearly all studies, patients were on concomitant therapies, limiting the ability to discern whether a specific intervention was related to the outcome. Following a formal risk of bias

assessment, 23 (32%) studies were rated as good, 37 (52%) fair and 11 (15%) poor. Publication bias, assessed by observation of funnel plots and Egger's test, was not present for any of the outcomes assessed (Figure S2).

Tocilizumab

Twelve prospective studies with a control arm, eight prospective studies without a control arm, and 40 retrospective studies examining the clinical impact of tocilizumab in Covid-19 were identified. Amongst the prospective studies there were six randomised clinical trials (RCTs). In total, the studies reported outcomes from 20,972 patients, of whom 6563 (31%) were given tocilizumab. Criteria for eligible participants varied across the studies, with many specifying respiratory failure with laboratory evidence of hyperinflammation as a prerequisite. The dose of tocilizumab administration was not entirely consistent with intravenous 8mg/kg or 400mg the most commonly studied route and dose.

Ordinal scale

A total of 12 studies provided outcomes on an adapted 4-point scale for 1782 patients including cases and controls (Table S4). The median time for reporting outcomes after treatment was 14 days (IQR 14-28). The recently available REMAP-CAP adaptive RCT interim analysis reported a signal that tocilizumab was associated with clinical improvement at day 14 (aOR 1.83 95%CI 1.40;2.41)(20), whilst in a separate RCT, outcomes on an ordinal severity scale did not differ between the treatment groups (HR 1.06 95%CI 0.80;1.41)(21). Distinctions in statistical methodology and clinical endpoints precluded inclusion of these

RCT in the specified meta-analysis. Tocilizumab was not associated with better outcomes on the ordinal scale in meta-analysis of the remaining prospective studies, including three RCTs (GenOR 1.09 95% CI 0.99;1.19, $I^2 = 84.3\%$) (Figure 3). Variability in reported concomitant steroid administration had a significant contribution upon the substantial heterogeneity observed (Table S5). Tocilizumab was associated with better outcomes in meta-analysis of retrospective studies, indicating a 34% greater chance of less-severe outcomes on the adapted ordinal scale when compared to control (GenOR 1.34 95% CI 1.10;1.64, $I^2 = 98\%$). However, these results should be interpreted with caution as there was severe heterogeneity which could not be explained by variability in the factors assessed.

Duration of hospitalisation

Two RCTs and nine retrospective studies reported the duration of hospitalisation for a total of 1553 survivors who received tocilizumab (Figure 4). Individual RCTs comparing the duration of hospitalisation with controls identified associations of tocilizumab with a reduced hospital stay (-0.34 days 95%CI -0.55;-0.12)(22) and earlier hospital discharge (aHR 1.41 95%CI 1.18;1.70)(20). Retrospective studies reporting the duration of hospitalisation were combined to give an overall summary estimate (20.98 days 95%CI 16.19;25.78, $I^2 = 97.1\%$), which was greater than the duration reported by RCTs (14.55 days 95%CI - 0.37;29.67, $I^2 = 99.9\%$). Compared with 943 patients in retrospective studies who received SOC only, tocilizumab was not associated with a difference in the mean duration of hospital stay (0.36 days 95% CI -0.07;0.80, $I^2 = 93.8\%$), with variability in route of administration (intravenous or subcutaneous) associated with the severe heterogeneity in this estimate (R² = 81.64%, p<0.001).

Overall mortality

Twenty-two studies totalling 13,702 patients reported adjusted hazard ratios for overall mortality, at a follow up time censored at a median of 28 days (IQR 14-30). Amongst the studies, two were RCTs and neither reported a difference between tocilizumab and control for mortality (21, 23). When prospective tocilizumab studies were pooled there was an emerging survival benefit, but the estimate was inconclusive (HR 0.70 95%Cl 0.44;1.10, $l^2 = 0\%$) (Figure 5). In the remaining retrospective studies, tocilizumab was associated with a 47% lower risk of adjusted mortality with substantial heterogeneity (HR 0.54 95%Cl 0.41;0.71, $l^2 = 85.9\%$). Meta-regression identified non-peer reviewed manuscripts as a significant source of heterogeneity (R² = 88.58, p<0.001).

Risk ratios (RR) were calculated from 42 studies, including six RCTs, reporting unadjusted mortality data for 15,085 patients at a median follow up of 24 days (IQR 14-28) (Figure 6). Tocilizumab was associated with a 17% lower unadjusted risk of mortality compared with the control arm in prospective studies (RR 0.83 95%CI 0.72;0.96, $I^2 = 0.0\%$), which did not reach significance in RCTs alone (RR 0.85 95%CI 0.71;1.01 $I^2 = 0.0\%$) (Figure S3). Within retrospective studies, tocilizumab was associated with a 24% lower risk of mortality (RR 0.76 95%CI 0.64;0.92, $I^2 = 80.3\%$), although there was substantial heterogeneity which could not be explained by variability in the factors assessed. The combined case fatality (CFR) across all studies included in the meta-analysis was 21.2% (1118/5284) in the intervention arm and 31.1% (3049/9801) in the control arm. The CFR from single arm prospective studies unable to be included in meta-analysis was 17.8% (113/634).

Other immuno modulators

Studies exploring outcomes in patients who received anakinra, sarilumab or siltuximab were not quantitively synthesised for all outcomes, owing to differences in outcomes reported, study design and limited study numbers. Similar to studies in tocilizumab, participant criteria were inconsistent but typically included patients with respiratory failure and signs of hyperinflammation. Doses of therapeutic agents ranged from 200-600mg daily for anakinra, and 200-400mg daily for sarilumab. In all studies, patients received concomitant medications including but not limited to antivirals, hydroxychloroquine and corticosteroids. Meta-analysis inclusive of all immunomodulatory agents without sub analysis are presented in Figures S4-S7.

Anakinra

Four prospective and three retrospective studies exploring outcomes in 346 patients who received anakinra and 3339 controls were retrieved. Three studies reported ordinal outcome data for both anakinra and control participants, although the outcome day varied. Anakinra was associated with improved clinical outcomes in two retrospective studies of 22 and 45 patients, respectively (24, 25). A similar association with improved clinical outcomes was reported on day 14 in a prospective study of 69 patients (GenOR 1.77 95%CI 1.52;2.06)(26). Two studies reported adjusted HR for mortality with supportive results. A significant association was not observed in a retrospective study of 57 treated patients (aHR

0.79 95%Cl 0.44;1.42)(27), whilst an association was observed in a prospective study of 130 patients (aHR 0.49 95%Cl 0.26;0.91)(28). A significant unadjusted association was also observed in a further study of 52 patients treated with anakinra (HR 0.30; 95%Cl 0.12-0.71)(29). Risk ratios were calculated from four studies totalling 424 participants. In a retrospective study of 29 treated patients, anakinra improved survival (RR 0.24 95%Cl 0.07;0.79); associations were inconclusive when prospective studies were pooled (RR 0.70 95%Cl 0.31;1.58, $I^2 = 32.8\%$) (Figure S8). No studies compared the duration of hospitalisation between recipients and non-recipients of anakinra.

Sarilumab

Five prospective studies exploring outcomes in 389 participants who received sarilumab were included. In the only RCT identified, sarilumab was associated with increased survival (aOR 2.01 95%Cl 1.18;4.71), reduced duration of hospitalisation (aHR 1.60 95%Cl 1.17;2.40) and improved ordinal outcomes at day 14 (aOR 1.86 95%Cl 1.22;2.91)(20). In a further non-randomised study of 28 participants (30), sarilumab was not significantly associated with mortality (aHR 0.36 95%Cl 0.08;1.68) and comparable effects were observed amongst treated and non-treated patients with respect to ordinal outcomes (GenOR 1.07 95%Cl 0.90;1.27) and duration of hospitalisation (mean difference 0.02 95%Cl -0.51;0.54). The combined CFR across the five included studies was 11% (43/389) for sarilumab, whilst in the only study reporting control mortality data the CFR was 35.8% (142/397).

Siltuximab

A single prospective cohort study of siltuximab studying outcomes in 60 patients was identified(31). Neither ordinal outcome data nor duration of hospitalisation were reported, but the adjusted risk of mortality was reported to be significantly lower in patients who received siltuximab (aHR 0.46 95%CI 0.22;0.97).

Treatment related adverse events

Treatment related adverse events were reported in most studies (70%) and typically included secondary bacterial infections and derangement of liver enzymes (Table 2). In studies with a comparator arm exploring outcomes from patients who received anakinra or sarilumab, the frequency of treatment related adverse events was similar in both treatment and comparator groups. Findings from studies reporting outcomes following tocilizumab administration were inconsistent. In five studies, tocilizumab recipients had an increased prevalence of secondary infections compared with controls. However, in twelve studies, tocilizumab was associated with a lower or similar rate of secondary infections compared with controls.

Clinical trials

Sixty-two planned or in-process clinical trials (tocilizumab, 44; siltuximab, 4; sarilumab, 9; anakinra, 13) were identified through clinical registry searches, with some clinical trials exploring more than one immunomodulatory agent. Currently registered clinical trials and their estimated dates of completion are provided in Figure S9.

DISCUSSION

In this systematic review and meta-analysis, we summarise and evaluate the association between immunomodulatory agents and multiple outcomes in Covid-19. Although there was severe heterogeneity across tocilizumab studies exploring outcomes on an adapted four-point ordinal scale, a beneficial effect of tocilizumab was suggested in retrospective studies compared with controls. Prospective studies followed a similar direction of association, though confidence intervals were not conclusive. The certainty of the findings related to the adapted ordinal severity scale are assessed as moderate using GRADE (Table S6). The mean duration of hospitalisation was not altered by intervention, with low certainty of findings. Tocilizumab was associated with a survival benefit that was consistent across retrospective and prospective studies, with pooled analysis of unadjusted risk ratios demonstrating a 17% reduced risk of mortality in prospective studies. We assess the certainty of our findings related to overall mortality as high.

Due to heterogeneity in study designs and reported outcomes, studies in patients receiving immunomodulatory agents other than tocilizumab were not quantitatively synthesised for all outcomes. In the only study reporting adjusted HRs, anakinra was associated with reduced mortality. However, pooled analysis of unadjusted ratios in non-randomised studies did not demonstrate a mortality benefit. A single sarilumab RCT demonstrated that intervention was associated with improved outcomes and reduced hospital stay. No randomised studies were identified for siltuximab. For all agents included in this review, the

frequency of adverse events was similar in the treatment and control arms. Sixty-one registered clinical trials exploring immunomodulatory agents in Covid-19 were identified, of which some have completed and been published.

In this review we highlight multiple limitations and considerable sources of inter-study heterogeneity. The majority of included studies were non-randomised cohorts of relatively modest size. Although most studies necessitated respiratory failure requiring at least basic respiratory support, participant criteria were not entirely consistent across the studies. The dosage and delivery of therapy varied across many of the non-randomised studies, and in nearly all studies patients were on concomitant medications such as antivirals, hydroxychloroquine and steroids with administration at the discretion of the treating physician, precluding causal associations of specific interleukin inhibitors with outcomes. Study outcomes were heterogeneous and a combination of clinical, laboratory and radiological outcomes were reported, rather than a single consistent endpoint. Furthermore, there was inconsistency in the duration of follow up and timing of reported outcomes. Individual patient data (IPD) may have mitigated some of these limitations, but in a rapidly progressing area, seeking IPD was deemed to be unrealistic due to the associated delays. We also observed significant statistical heterogeneity as measured by I², and therefore the findings of our meta-analysis should be interpreted with caution. We were unable to explain all the residual heterogeneity using the factors we assessed, although concomitant steroid use, route of drug administration and non-peer reviewed manuscript appeared to contribute within specific outcomes.

To maximise value and timeliness of our review of four specific immunomodulators, two primary endpoints and a number of secondary endpoints, we included both retrospective and preprint studies. Risk of bias was minimised by restricting analysis of non-prospective studies to those with a control group, and caution is used to present summaries separately. We did not detect any significant publication bias in the reporting of effects. Where there was insufficient data for meta-analysis, summary outcomes were presented with qualitative synthesis to ensure the review was comprehensive. The data presented here represent findings from different countries, offering diversity in ethnic background. We were unable to identify suitable studies in SARS or MERS to comment on the generalisability of immunomodulators in other coronavirus outbreaks.

In conclusion, this systematic review provides the most up-to-date and complete evidence for a range of specific immunomodulatory therapies in the management of Covid-19. We have established that evidence for the efficacy of anakinra, siltuximab or sarilumab in Covid-19 is currently insufficient and adequately powered high-quality randomised clinical studies are urgently needed. We demonstrate through quantitative synthesis of retrospective studies that tocilizumab intervention was frequently associated with improved outcomes and reduced mortality. However, data were highly heterogeneous and must be interpreted with caution. Prospective studies demonstrated a 17% lower unadjusted risk of mortality with tocilizumab, with minimal heterogeneity and similar adjusted estimates. Further research should focus on identifying participant and disease characteristics where immunomodulatory therapy is likely to be of maximal effectiveness, whilst also exploring the relationship with baseline inflammatory biomarkers such as interleukin-6 and C reactive

protein. In summary, we demonstrate tocilizumab is associated with lower mortality in

Covid-19, and other immunomodulatory therapies are worth exploring further.

Funding: FK/LF/IS/AS are supported by the Nottingham National Institute for Health Research (NIHR) Biomedical Research Centre. RGJ is supported by an NIHR Research Professorship (RP-2017-08-ST2-014).

References

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497-506.

2. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 2020 [Available from: <u>https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</u>.

3. Johns Hopkins University of Medicine

COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). <u>https://coronavirusjhuedu/maphtml</u>.

4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033-4.

5. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020.

6. Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis. medRxiv. 2020:2020.03.30.20048058.

7. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463-9.

8. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of proinflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2).

9. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection. 2020;48(2):155-63.

10. Hui DS, E IA, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264-6.

11. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103.

12. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8-13.

13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj. 2009;339:b2700.

14. National Heart L, National Institute of Health. <u>https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools</u> [

15. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:14898.

16. Granholm A, Alhazzani W, Møller MH. Use of the GRADE approach in systematic reviews and guidelines. Br J Anaesth. 2019;123(5):554-9.

17. Churilov L, Arnup S, Johns H, Leung T, Roberts S, Campbell BCV, et al. An Improved Method for Simple, Assumption-Free Ordinal Analysis of the Modified Rankin Scale Using Generalized Odds Ratios. International Journal of Stroke. 2014;9(8):999-1005.

18. McGrath S, Zhao X, Steele R, Thombs BD, Benedetti A. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Statistical Methods in Medical Research. 2020;29(9):2520-37.

19. WebPlotDigitizer. <u>https://apps.automeris.io/wpd/</u> [

20. Gordon AC. Interleukin-6 Receptor Antagonists in Critically III Patients with Covid-19 - Preliminary report. medRxiv. 2021:2021.01.07.21249390.

21. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. New England Journal of Medicine. 2020.

22. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. New England Journal of Medicine. 2020.

23. Hermine O, Mariette X, Tharaux P-L, Resche-Rigon M, Porcher R, Ravaud P, et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Internal Medicine. 2020.

24. Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco VB, et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proceedings of the National Academy of Sciences. 2020;117(32):18951-3.

25. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet Rheumatology. 2020;2(6):e325-e31.

26. Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S, BaTaher H, et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study. International Journal of Infectious Diseases. 2020;17:17.

27. Narain S, Stefanov DG, Chau AS, Weber AG, Marder G, Kaplan B, et al. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm. Chest. 2020;17:17.

28. Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, Gatselis N, et al. Anakinra To Prevent Respiratory Failure In COVID-19. medRxiv. 2020:2020.10.28.20217455.

29. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. The Lancet Rheumatology. 2020;2(7):e393-e400.

30. Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study. Annals of the rheumatic diseases. 2020; (no pagination).

31. Gritti G, Raimondi F, Ripamonti D, Riva I, Landi F, Alborghetti L, et al. IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study. medRxiv. 2020:2020.04.01.20048561.

32. Roumier M, Paule R, Vallée A, Rohmer J, Ballester M, Brun A-L, et al. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis. Journal of clinical immunology. 2020:1-12.

33. Kimmig LM, Wu D, Gold M, Pettit NN, Pitrak D, Mueller J, et al. IL-6 Inhibition in Critically III COVID-19 Patients Is Associated With Increased Secondary Infections. Frontiers in Medicine. 2020;7(689).

34. Klopfenstein T, Zayet S, Lohse A, Selles P, Zahra H, Kadiane-Oussou NJ, et al. Impact of Tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020;12.

35. Kooistra EJ, Waalders NJB, Grondman I, Janssen NAF, de Nooijer AH, Netea MG, et al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Critical Care (London, England). 2020;24(1):688.

36. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Internal Medicine. 2020.

37. Lewis TC, Adhikari S, Tatapudi V, Holub M, Kunichoff D, Troxel AB, et al. A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019. Critical Care Explorations. 2020;2(11):e0283.

38. Sanchez-Montalva A, Selares-Nadal J, Espinosa-Pereiro J, Fernandez-Hidalgo N, Perez-Hoyos S, Salvador F, et al. Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study. medRxiv. 2020:2020.05.07.20094599.

39. Martínez-Sanz J, Muriel A, Ron R, Herrera S, Pérez-Molina JA, Moreno S, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study. Clinical Microbiology and Infection.

40. Sciascia S, Apra F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clinical and experimental rheumatology. 2020;38(3):529-32.

41. Nasa P, Singh A, Upadhyay S, Bagadia S, Polumuru S, Shrivastava PK, et al. Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers. Indian Journal of Critical Care Medicine. 2020;24(9):771-6.

42. Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, et al. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clinical Pharmacology & Therapeutics.n/a(n/a).

43. Patel K, Gooley TA, Bailey N, Bailey M, Hegerova L, Batchelder A, et al. Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients. Journal of Internal Medicine.n/a(n/a).

44. Benucci M, Giannasi G, Cecchini P, Gobbi FL, Damiani A, Grossi V, et al. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients. Journal of Medical Virology. 2020.

45. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmunity Reviews. 2020;19(7).

46. Petrak RM, Van Hise NW, Skorodin NC, Fliegelman RM, Chundi V, Didwania V, et al. Early Tocilizumab Dosing is Associated with Improved Survival In Critically III Patients Infected With Sars-CoV-2. medRxiv. 2020:2020.10.27.20211433.

47. Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. The Lancet Rheumatology. 2020.

48. Pettit NN, Nguyen CT, Mutlu GM, Wu D, Kimmig L, Pitrak D, et al. Late onset infectious complications and safety of tocilizumab in the management of COVID-19. Journal of Medical Virology. 2020.

49. Canziani LM, Trovati S, Brunetta E, Testa A, De Santis M, Bombardieri E, et al. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. Journal of Autoimmunity. 2020; (no pagination).

50. Potere N, Di Nisio M, Rizzo G, La Vella M, Polilli E, Agostinone A, et al. Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020;05.

51. Gremese E, Cingolani A, Bosello SL, Alivernini S, Tolusso B, Perniola S, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine.

52. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. European journal of internal medicine. 2020;76:31-5.

53. Ramaswamy M, Mannam P, Comer R, Sinclair E, McQuaid DB, Schmidt ML. Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study. medRxiv. 2020:2020.05.14.20099234.

54. Sinha P, Mostaghim A, Bielick CG, McLaughlin A, Hamer DH, Wetzler LM, et al. Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge. International Journal of Infectious Diseases. 2020;99:28-33.

55. Chilimuri S, Sun H, Alemam A, Kang KS, Lao P, Mantri N, et al. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study. Journal of Clinical Pharmacy & Therapeutics. 2020;24:24.

56. Rodriguez-Bano J, Pachon J, Carratala J, Ryan P, Jarrin I, Yllescas M, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clinical Microbiology & Infection. 2020;27:27.

57. De Rossi N, Scarpazza C, Filippini C, Cordioli C, Rasia S, Mancinelli CR, et al. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. EClinicalMedicine. 2020;25:100459.

58. Rojas-Marte G, Khalid M, Mukhtar O, Hashmi AT, Waheed MA, Ehrlich S, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a casecontrolled study. QJM : monthly journal of the Association of Physicians. 2020;113(8):546-50.

59. Albertini L, Soletchnik M, Razurel A, Cohen J, Bidegain F, Fauvelle F, et al. Observational study on off-label use of tocilizumab in patients with severe COVID-19. European Journal of Hospital Pharmacy Science & Practice. 2020;10:10. 60. Eimer J, Vesterbacka J, Svensson AK, Stojanovic B, Wagrell C, Sonnerborg A, et al. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study. Journal of Internal Medicine. 2020.

61. Roomi S, Ullah W, Ahmed F, Farooq S, Sadiq U, Chohan A, et al. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review. Journal of medical Internet research. 2020;22(9):e21758.

62. Antony SJ, Davis MA, Davis MG, Almaghlouth NK, Guevara R, Omar F, et al. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management. Journal of Medical Virology. 2020;09:09.

63. Fisher MJ, Raymundo LAM, Monteforte M, Taub EM, Go R. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia: A Retrospective Cohort Study of Mechanically Ventilated Patients. International Journal of Infectious Diseases. 2020;14:14.

64. Rosas J, Liano FP, Canto ML, Barea JMC, Beser AR, Rabasa JTA, et al. Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study. Reumatologia Clinica. 2020.

65. Campins L, Boixeda R, Perez-Cordon L, Aranega R, Lopera C, Force L. Early tocilizumab treatment could improve survival among COVID-19 patients. Clinical and experimental rheumatology. 2020;38(3):578.

66. Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, Marcos-Jiménez A, Sánchez-Alonso S, Fernández-Díaz C, et al. IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol. 2020.

67. Rossi B, Nguyen LS, Zimmermann P, Boucenna F, Dubret L, Baucher L, et al. Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study. Pharmaceuticals. 2020;13(10):17.

68. Carvalho V, Turon R, Goncalves B, Ceotto V, Kurtz P, Righy C. Effects of Tocilizumab in Critically III Patients With COVID-19: A Quasi-Experimental Study. medRxiv. 2020:2020.07.13.20149328.

69. Moreno Garcia E, Rico Caballero V, Albiach L, Aguero D, Ambrosioni J, Bodro M, et al. Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. medRxiv. 2020:2020.06.05.20113738.

70. Rossotti R, Travi G, Ughi N, Corradin M, Baiguera C, Fumagalli R, et al. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. Journal of Infection. 2020;08:08.

71. Dastan F, Saffaei A, Haseli S, Marjani M, Moniri A, Abtahian Z, et al. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. International Immunopharmacology. 2020;88 (no pagination).

72. Gokhale Y, Mehta R, Karnik N, Kulkarni U, Gokhale S. Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia. EClinicalMedicine. 2020;24 (no pagination).

73. Ruiz-Antorán B, Sancho-López A, Torres F, Moreno-Torres V, de Pablo-López I, García-López P, et al. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study. Infectious Diseases and Therapy. 2020. 74. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology. 2020;2(8):e474-e84.

75. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;11.

76. Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM, Roda-Santacruz A, González-Cortijo L, Sotres-Fernández G, et al. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine.

77. Tian J, Zhang M, Jin M, Zhang F, Chu Q, Wang X, et al. Repurposed Tocilizumab in Patients with Severe COVID-19. Journal of immunology. 1950(pagination).

78. Malekzadeh R, Abedini A, Mohsenpour B, Sharifipour E, Ghasemian R, Javad-Mousavi SA, et al. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. International Immunopharmacology. 2020;89:107102.

79. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association Between Early Treatment With Tocilizumab and Mortality Among Critically III Patients With COVID-19. JAMA Internal Medicine. 2020.

80. Tsai A, Diawara O, Nahass RG, Brunetti L. Impact of tocilizumab administration on mortality in severe COVID-19. Scientific Reports. 2020;10(1):19131.

81. Mikulska M, Nicolini LA, Signori A, Di Biagio A, Sepulcri C, Russo C, et al. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. PLoS ONE [Electronic Resource]. 2020;15(8):e0237831.

82. Hill JA, Menon MP, Dhanireddy S, Wurfel MM, Green M, Jain R, et al. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. Journal of Medical Virology.n/a(n/a).

83. Wadud N, Ahmed N, Mannu Shergil M, Khan M, Krishna MG, Gilani A, et al. Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration. medRxiv. 2020:2020.05.13.20100081.

84. Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. European Journal of Internal Medicine. 2020;76:36-42.

85. Holt GE, Batra M, Murthi M, Kambali S, Santos K, Bastidas MVP, et al. Lack of tocilizumab effect on mortality in COVID19 patients. Scientific Reports. 2020;10(1):17100.

86. Zheng K-L, Xu Y, Guo Y-F, Diao L, Kong X-Y, Wan X-J, et al. Efficacy and safety of tocilizumab in COVID-19 patients. Aging. 2020;12(19):18878-88.

87. Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, et al. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Journal of Translational Medicine. 2020;18(1):405.

88. Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclaire BA, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. PloS one. 2020;15(8 August).

89. Rosas I, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia. medRxiv. 2020:2020.08.27.20183442.

90. Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. EClinicalMedicine. 2020;24 (no pagination).




Figure 1 - Flow diagram illustrates systematic search and screening strategy, including numbers meeting eligibility criteria and numbers excluded. Last search carried out on 7th January 2021




Figure 2 - Summary of risk of bias assessment

A - Randomised clinical trials assessed using Cochrane risk of bias 2 tool (n=6). Risk of bias was assessed in six categories and scored as either low risk of bias, some concern, or high risk of bias, before an overall risk of bias was given to each study.

B - Non-randomised prospective studies (n=23). Questions numbered in the first column. 1. Was the research question or objective in this paper clearly stated? 2. Was the study population clearly specified and defined? 3. Was the participation rate of eligible persons at least 50%? 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? 5. Was a sample size justification, power description, or variance and effect estimates provided? 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? 10. Was the exposure(s) assessed more than once over time? 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? 12. Were the outcome assessors blinded to the exposure status of participants? 13. Was loss to follow-up

after baseline 20% or less? 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?

C - Summary of risk of bias assessment for retrospective studies (n=42). Questions numbered in first column. 1. Was the research question or objective in this paper clearly stated and appropriate? 2. Was the study population clearly specified and defined? 3. Did the authors include a sample size justification? 4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)? 5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants? 6. Were the cases clearly defined and differentiated from controls? 7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible? 8. Was there use of concurrent controls? 9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case? 10. Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants? 11. Were the assessors of exposure/risk blinded to the case or control status of participants? 12. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis?




Figure 3 – Tocilizumab generalised odds ratios (OR) for ordinal outcome forest plot. Generalised OR shown for each study with 95% confidence interval and day at which ordinal outcome recorded. Sample sizes given for patients receiving intervention (n) alongside total included (N) in study. Summary estimates presented separately for prospective and retrospective studies.

* non peer-reviewed preprint studies

randomised controlled trials




Figure 4 – Tocilizumab duration of hospitalisation (days) forest plot. **A**: Mean duration of hospital stay. **B**: Mean difference compared with controls in duration of hospital stay. Effect sizes and associated 95% confidence intervals presented for each study. Sample sizes given for patients receiving intervention (n) and total included in study (N). Summary estimates presented separately for prospective and retrospective studies.

Author	Year	aHR (95% CI)	% Weight	n/N	Day
Retrospective					
*Martinez-Sanz	2020	+ 1.53 (1.20, 1.96)	7.39	260/1229	6
*Ramaswamy	2020	0.25 (0.07, 0.90)	2.94	21/86	7
Ruiz-Antoran	2020 🔹	0.74 (0.62, 0.89)	7.59	238/506	12
Guaraldi	2020	0.38 (0.17, 0.83)	4.77	179/544	14
Rodriguez-Bano	2020 —	0.12 (0.02, 0.56)	2.04	88/432	21
Biran	2020 🔸	0.64 (0.47, 0.87)	7.15	210/630	22
Gupta	2020 +	0.71 (0.56, 0.92)	7.38	433/3925	27
Hill	2020	0.57 (0.21, 1.52)	3.91	43/88	28
Rossi	2020 +	0.42 (0.22, 0.82)	5.43	84/168	28
Somers	2020 +	0.55 (0.33, 0.90)	6.23	78/154	28
Canziani	2020 -	0.82 (0.42, 1.58)	5.41	64/128	30
De Rossi	2020 —	0.06 (0.02, 0.19)	3.41	90/158	30
Eimer	2020	0.52 (0.19, 1.39)	3.89	22/44	30
lp	2020 🔸	0.76 (0.57, 1.00)	7.25	134/547	30
Gokhale	2020 -+	0.62 (0.38, 0.99)	6.35	70/161	31
Lowis	2020 +	0.24 (0.18, 0.33)	7.17	497/994	NB
Narain	2020 -	0.79 (0.47, 1.32)	6.16	73/3149	NR
Tian	2020 -	0.47 (0.25, 0.90)	5.52	65/195	NB
Subtotal (I-squar	ed = 85.9%, p = 0.000) 🔇	0.53 (0.41, 0.71)	100.00		
Prospective	_				
#Hermine	2020 —	• 0.92 (0.33, 2.53)	20.25	63/130	28
Roumier	2020	0.68 (0.31, 1.75)	28.04	49/96	28
#Stone	2020 —	• 1.52 (0.41, 5.61)	12.27	161/243	28
Mikulska	2020	0.48 (0.23, 0.99)	39.43	29/95	30
Subtotal (I-squar	ed = 0.0%, p = 0.448)	0.70 (0.44, 1.10)	100.00		
NOTE: Weights a	re from random effects analys	is			
	.01	1 10			

Figure 5 – Tocilizumab adjusted hazard ratios (HR) for overall mortality forest plot. Adjusted HRs with associated 95% confidence interval and day of censorship presented for each study. Sample sizes given for patients receiving intervention (n) and total included (N) in study. Summary estimates presented separately for prospective and retrospective studies. * non peer-reviewed preprint studies

randomised controlled trials

NR, not reported

Author	Year	RR (95% Cl)	% Weight	n/N	Day
Retrospective					
Martinez-Sanz	2020	1.89 (1.44, 2.50)	4.82	260/1229	6
Patel	2020	0.80 (0.37, 1.72)	2.78	42/83	7
Ramaswamy	2020	1.14 (0.33, 3.92)	1.58	21/85	7
Capra .	2020	0.07 (0.02, 0.28)	1.27	62/85	9
Guaraldi	2020	0.31 (0.16, 0.60)	3.12	179/544	14
Kewan	2020	1.23 (0.22, 6.76)	0.96	28/51	14
Zheng	2020	8.71 (1.13, 67.32)	0.70	9/2/181	16
Ruiz-Antoran	2020 🔶	0.53 (0.38, 0.74)	4.62	268/506	18
Rodriguez-Bano	2020	0.19 (0.05, 0.77)	1.31	88/432	21
Biran	2020	0.80 (0.68, 0.93)	520	210/630	22
Gupta	2020	0.71 (0.61, 0.83)	5.21	433/3925	27
HIII	2020	0.63 (0.31, 1.28)	2.98	43/88	28
Nasa	2020	0.16 (0.04, 0.61)	1.40	22/85	28
Somers	2020	0.49 (0.28, 0.85)	3.61	78/154	28
Canziani	2020	0.71 (0.42, 1.19)	3.79	64/128	90
De Rossi	2020	0.16 (0.07, 0.33)	2.85	90/158	30
Eimer	2020	0.71 (0.27, 1.91)	212	22/44	30
Fisher	2020 🔶	0.72 (0.42, 1.24)	3.68	46/115	30
Rosas, J.	2020	0.57 (0.19, 1.68)	1.87	20/37	30
Gokhale	2020 🔶	0.70 (0.53, 0.94)	4.78	70/161	31
Galvan-Roman	2020	1.33 (0.70, 2.51)	3.28	58/146	61
Guisado-Vasco	2020	1.63 (1.21, 2.20)	4.73	1 32/607	NIB
Kimmig	2020	1.82 (0.96, 3.47)	3.26	54/111	NB
Kiopfenstein	2020	0.52 (0.22, 1.23)	2.47	20/45	NB
Lewis	2020	0.69 (0.58, 0.82)	5.17	497/994	NB
Pettit	2020	1.71 (1.03, 2.83)	3.84	74/148	NR
Rojas-Marte	2020 🔶	0.79 (0.60, 1.05)	4.80	96/193	NB
Roomi	2020 +	2.08 (0.85, 5.05)	2.39	3/2/176	NB
Tizan	2020 🔶	0.67 (0.39, 1.13)	3.75	66/195	NB
Tarai	2020 🚽	1.00 (0.57, 1.75)	3.61	66/132	NIB
'Wadud	2020 🔶	0.74 (0.47, 1.17)	4.05	44/94	NB
Subtotal (I-squared	= 80.3%, p = 0.000)	0.76 (0.64, 0.92)	100.00		
Prospective					
Albertini	2020	1.01 (0.07, 15.25)	0.30	22/44	14
'Carvalho	2020	1.03 (0.31, 3.43)	1.52	29/53	14
#Hermine	2020	1.24 (0.44, 3.49)	2.04	63/130	14
Perrone	2020 🔶	0.78 (0.58, 1.05)	25.33	708/1189	14
fSalvarani	2020	1.05 (0.07, 16.41)	0.29	60/123	14
#Rosas,I.	2020 🔶	0.87 (0.58, 1.33)	12.53	294/438	28
Roumier	2020	1.15 (0.38, 3.52)	1.75	49/96	28
/Salama	2020 -	1.22 (0.62, 2.38)	4.84	249/377	28
#Stone	2020	1.44 (0.40, 5.17)	1.34	156/231	28
Mikulska	2020	0.57 (0.21, 1.55)	2.16	29/95	30
#Gordon	2021	0.78 (0.63, 0.97)	47.90	350/747	NB
Subtotal (I-squared	= 0.0%, p = 0.944)	0.63 (0.72, 0.96)	100.00		
NOTE: Weights are	from random effects analysis				
	.01 1	10.20			

Figure 6 – Tocilizumab mortality risk ratios (RR) forest plot. Risk ratios with associated 95% confidence interval and day of censorship presented for each study. Sample sizes given for patients receiving intervention (n) and total included in study (N). Summary estimates presented separately for prospective and retrospective studies.

- * non peer-reviewed preprint studies
- # randomised controlled trials
- NR, not reported

Author, year	Drug	N, Tx/ Control	Study country	Centre	Study design	Author, year	Drug	N, Tx/ Control	Study country	Centre	Study design	Author, year	Drug	N,Tx/ Control	Study country	Centre	Study desi Retrospect
Balkhair, 2020(26)	А	45/24	Oman	single centre	Prospective with control	Roumier, 2020(32)	Т	49/47	France	single centre	Prospective with control	Kimmig, 2020(33)	Т	54/57	USA	single centre	Retrospect
Huet <i>,</i> 2020(29)	A	52/44	France	single centre	Prospective with control	Salama, 2020(22)	Т	249/ 128	USA	multi- centre	Double blind RCT	Klopfenste in, 2020(34)	т	20/25	France	single centre	Retrospect
Kooi stra, 2020(35)	А	21/39	Netherla nds	multi- centre	Prospective with control	Salvarani, 2020(36)	Т	60/63	ltaly	multi- centre	Open label RCT	Le wis, 2020(37)	Т	497/497	USA	multi- centre	Retrospect
*Kyriazopoul ou, 2020(28)	А	130/130	Greece	multi- centre	Prospective	*Sanchez- Montalva, 2020(38)	Т	82/0	Spain	single centre	Prospective	Martinez- Sanz, 2020(39)	т	260/969	Spain	multi- centre	Retrospect
Cauchoi <i>s,</i> 2020(24)	A	12/10	France	multi- centre	Retrospective	Sciascia, 2020(40)	т	63/0	ltaly	multi- centre	Prospective	Narain, 2020(27)	Т	73/3076	USA	multi- centre	Retrospect
Cavalli, 2020(25)	A	29/16	ltaly	single centre	Retrospective	Stone, 2020(21)	т	161/ 82	USA	multi- centre	Double blind RCT	Nasa, 2020(41)	Т	22/63	India	multi- centre	Retrospect Retrospect Retrospect Retrospect
Narain, 2020(27)	А	57/3076	USA	multi- centre	Retrospective	Strohbehn, 2020(42)	Т	32/41	USA	single centre	Phase 2 open label	Patel, 2020(43)	Т	60/1505	USA	single centre	Retrospect
Benucci, 2020(44)	Sa	8/0	ltaly	single centre	Prospective	Toniati, 2020(45)	Т	100/0	lt al y	single centre	Prospective	* Petrak, 2020(46)	т	81/37	USA	multi- centre	Retrospect
Della-Torre, 2020(30)	Sa	28/28	ltaly	single centre	Prospective with control	Biran, 2020(47)	т	210/ 420	USA	multi- centre	Retrospective	Pettit, 2020(48)	Т	42/41	USA	single centre	Retrospect Retrospect Retrospect Retrospect
* Gordon, 2021 (20)	Sa	45/397	UK	multi- centre	Adaptive RCT	Canziani, 2020(49)	Т	64/64	ltaly	multi- centre	Retrospective	Potere, 2020(50)	Т	74/74	ltaly	single centre	Retrospect
Gremese, 2020(51)	Sa	53/0	lt al y	single centre	Prospective	Capra, 2020 (52)	Т	62/23	ltaly	single centre	Retrospective	* Ramaswa my, 2020(53)	Т	10/10	USA	multi- centre	Retrospect
Sinha, 2020(54)	Sa	255/0	USA	single centre	Prospective	Chillmuri, 2020 (55)	Т	83/ 685	USA	single centre	Retrospective	Rodriguez- Bano, 2020(56)	Т	21/65	Spain	multi- centre	Retrospect
*Gritti 2020(31)	Si	30/30	ltaly	single centre	Prospective with control	De Rossi, 2020(57)	т	90/68	Italy	single centre	Retrospective	Rojas- Marte, 2020(58)	т	88/344	USA	single centre	Retrospect

																	<u>S-</u>
Albertini, 2020(59)	т	22/22	France	single centre	Prospective with control	Eimer, 2020(60)	Т	22/22	Sweden	single centre	Retrospective	Roomi, 2020(61)	Т	96/97	USA	single centre	Retrospective
Antony, 2020(62)	т	80/0	USA	multi- centre	Prospective	Fisher, 2020(63)	Т	45/70	USA	single centre	Retrospective	Rosas, J.(64)	Т	20/17	Spain	single centre	Retrospective
Campins, 2020(65)	Т	58/0	Spain	single centre	Prospective	Galvan Roman, 2020(66)	Т	58/88	Spain	single centre	Retrospective	Rossi <i>,</i> 2020(67)	Т	84/84	France	single centre	Retrospective
* Carvalho, 202 0(68)	т	29/24	Brazil	single centre	Prospective with control	* Garcia, 2020(69)	Т	77/94	Spain	single centre	Retrospective	Rossotti, 2020(70)	Т	74/148	ltaly	single centre	Retrospective
Dast an, 202 0(71)	т	42/0	Iran	single centre	Prospective	Gokhale, 2020(72)	Т	70/91	India	single centre	Retrospective	Rui z- Ant or an, 2020(73)	Т	268/238	Spain	multi- centre	Retrospection
* Gordon, 2021(20)	Т	350/397	UK	multi- centre	Adaptive RCT	Guaral di , 2020(74)	Т	179/ 365	lt al y	multi- centre	Retrospective	Som er s, 2020(75)	Т	78/76	USA	single centre	author/ Retrospecti ∎ole
Hermine, 2020(23)	т	63/67	France	multi- centre	Op en-lab el RCT	Guisado- Vasco, 2020(76)	Т	132/ 475	Spain	single centre	Retrospective	Tian, 2020(77)	Т	65/130	China	multi- centre	Retrospectiver, a
Mal ekza de h, 202 0(78)	т	126/0	lran	multi- centre	Prospective	Gupta, 2020(79)	Т	433/ 3492	USA	multi- centre	Retrospective	Tsai, 2020(80)	Т	66/66	USA	single centre	Retrospective A
Mikulska, 2020(81)	т	29/66	ltaly	single centre	Prospective with control	Hill, 2020(82)	Т	43/45	USA	single centre	Retrospective	* Wadud, 2020(83)	Т	84/84	USA	single centre	Retrospective d
Morena, 2020(84)	Т	51/0	lt aly	single centre	Prospective	Holt, 2020(85)	Т	24/30	USA	single centre	Retrospective	Zheng, 2020(86)	Т	92/89	China	single centre	Retrospective Retrospective
Perrone 2020(87)	т	708/481	lt aly	multi- centre	Single arm open label & Validation	lp, 2020(88)	Т	134/413	USA	multi- centre	Retrospective						license
* Rosas, 2020(89)	Т	294/144	USA	multi- centre	Double blind RCT	Ke wan, 2020(90)	Т	28/23	USA	single centre	Retrospective						se to disp

 Table 1 – Included studies with study characteristics and sample size for treatment (Tx) and control group (control) shown.


* non peer-reviewed preprint study; #, study investigating both anakinra and tocilizumab; A, anakinra; Sa, sarilumab; Si, siltuximab; T, tocilizumab


Author, year	Therapy	Adverse effects
Balkhair, 2020	Anakinra	Treatment: infection (11%), ALT rise (14%). Control: infection (18%), ALT rise (9%)
Huet, 2020	Anakinra	Treatment: ALT rise (13%). Control: 9% in anakinra
Kooistra, 2020	Anakinra	Treatment: secondary infection (33%). Control: secondary infection (23%)
* Kyriazopoulou, 2020	Anakinra	Increased leukopenia in treatment group vs. controls (8.5% vs 2.3%; p=0.05)
Cauchois, 2020	Anakinra	N/R
Cavalli, 2020	Anakinra	Treatment: staphylococcus epidermis (14%); deranged liver enzymes (10%). Control: bacteraemia (13%); deranged liver enzymes (31%).
Narain, 2020	Anakinra	N/R
Benucci, 2020	Sarilumab	Nil
Della-Torre, 2020	Sarilumab	Treatment: Infections (21%); neutropenia (14%); liver enzyme increase (14%); thromboembolism (7%). Control: Infections (18%); thromboembolism (7%)
* Gordon, 2021	Sarilumab	No serious event in sarilumab group, and 11 events in control
Gremese, 2020	Sarilumab	neutropenia (15%); elevated liver enzymes (11%)
Sinha, 2020	Sarilumab or Tocilizumab	bacterial infection (13%)
* Gritti 2020	Siltuximab	Nil
Albertini, 2020	Tocilizumab	elevated liver enzymes (64%)
Antony, 2020	Tocilizumab	N/R
Campins, 2020	Tocilizumab	Nil
* Carvalho, 2020	Tocilizumab	Nil
Chillmuri, 2020	Tocilizumab	N/R
Dastan, 2020	Tocilizumab	transient diplopia (4.8%); Bell's palsy (2.4%)
* Gordon, 2021	Tocilizumab	9 serious adverse events in Tocilizumab group and 11 events in control
Hermine, 2020	Tocilizumab	Treatment: Serious adverse events occurred in 20 (32%). Control: 29 (43%) (Pऌ=ऌ.21)
Le wis, 2020	Tocilizumab	Increased infection rate in treatment group (aOR 4.18; 95% Cl 2.72-6.52)
Malekzadeh, 2020	Tocilizumab	Nil
Mikulska, 2020	Tocilizumab	N/R
Morena, 2020	Tocilizumab	elevated liver enzymes (29%), thrombocytopenia (14%), neutropenia (6%), infections (24%)
Nasa, 2020	Tocilizumab	two patients (9.1%) developed deranged LFTs and two patients (9.1%) developed secondary sepsis.
Perrone, 2020	Tocilizumab	allergic reactions (0.4%), deranged liver enzymes (10.5%)
* Petrak, 2020	Tocilizumab	N/R
* Rosas,1., 2020	Tocilizumab	66 serious infections (21%) were reported in the treatment arm and 49 (25.9%) in the placebo arm. Adverse events similar in both arms
Roumier, 2020	Tocilizumab	Treatment: higher rates of neutropenia (35% vs. 0%, p⊡<⊡0.001). Control: trend towards increased bacterial infections (22% vs. 38%, p⊡=⊡0.089; including ventilator-acquired pneumonia: 8% vs. 26%, p⊡=⊡0.022) and shorter time to infection (mean 18 vs. 10 days, p⊡=⊡0.029)

Salama, 2020	Tocilizumab	Serious adverse events occurred in 38 of 250 patients (15.2%) in the tocilizumab group and 25 of 127 patients (19.7%) in the placebo group.
Salvarani, 2020	Tocilizumab	Nil
* Sanchez-Montalva, 2020	Tocilizumab	Nil
Sciascia, 2020	Tocilizumab	Nil
Stone, 2020	Tocilizumab	Neutropenia developed in 22 patients in the treatment group, as compared with only 1 patient in the placebo group (P=0.002), but serious infections occurred in fewer patients in the tocilizumab group (13 [8.1%] vs. 14 [17.3%]; P=0.03).
Strohbehn, 2020	Tocilizumab	Treatment: bacterial infections (15.6%). Control: not reported
Toniati, 2020	Tocilizumab	septic shock (2%), gastrointestinal perforation (1%)
Biran, 2020	Tocilizumab	Treatment: secondary bacterial infection in 17%. Control: secondary bacterial infection in 13%
Canziani, 2020	Tocilizumab	HR 0.71 (95% Cl 0.38-1.32) for infection; HR 0.89 (95% Cl 0.39-2.06) for thrombosis; HR 1.17 (95% Cl 0.47-2.92) for bleeding
Capra, 2020	Tocilizumab	Nil
De Rossi, 2020	Tocilizumab	Significant rise (from 44.3 +/- 28.3 to 103 +/- 141.3) in ALT in patients taking IV dose
Eimer, 2020	Tocilizumab	Blood stream infection: 4 (18%) in treatment group vs. 6 (27%) in control
Fisher, 2020	Tocilizumab	No increased risk of secondary infection (OR 1.17; 95%Cl 0.51-2.71)
Galvan Roman, 2020	Tocilizumab	N/R
* Garcia, 2020	Tocilizumab	N/R
Gokhale, 2020	Tocilizumab	N/R
Guaraldi, 2020	Tocilizumab	13% treated diagnosed with new infections vs 4% in control (p<0.0001)
Guisado-Vasco, 2020	Tocilizumab	N/R
Gupta, 2020	Tocilizumab	Treated and control patients experienced the following adverse events: secondary infection (140 [32.3%] vs 1085 [31.1%]); AST or ALT level elevation of more than 250 U/L (72 [16.6%] vs 452 [12.9%])
Hill, 2020	Tocilizumab	In treatment vs control group, there was increased sepsis (21% and 16%), ALT rise (9% vs 4%) and thrombocytopenia (12% vs 4%)
Holt, 2020	Tocilizumab	N/R
p, 2020	Tocilizumab	N/R
Kewan, 2020	Tocilizumab	Similar rates of hospital-acquired infections occurred in both cohorts (18% in treatment and 22% in control).
Kimmig, 2020	Tocilizumab	Treatment associated with increased secondary bacterial (aOR 2.76; 95% Cl 1.11-7.2) and fungal (5.6% vs. 0%, p=0.112) infections
Klopfenstein, 2020	Tocilizumab	N/R
Martinez-Sanz, 2020	Tocilizumab	N/R
Narain, 2020	Tocilizumab	N/R
Patel, 2020	Tocilizumab	N/R
Pettit, 2020	Tocilizumab	Overall infection rate was similar (16.2% treatment vs. 17.5% control), but late on-set infections occurred in more treated patients (23% vs 8%; p=0.013). In treated, 26% experienced an increase to >5 times upper limit normal of LFTs
Potere, 2020	Tocilizumab	Nil
* Ramaswamy, 2020	Tocilizumab	N/R
Rodriguez-Bano, 2020	Tocilizumab	secondary bacterial infection similar in both groups (treated 12.5% vs. 10.3% control; p=0.57)
Rojas-Marte, 2020	Tocilizumab	Bacteraemia was more common in the control group (24% vs. 13%, PE=20.43), while fungemia was similar for both (3% vs. 4%, PE=20.72)
Roomi, 2020	Tocilizumab	N/R


Rosas, J. 2020	Tocilizumab	Nil	
Rossi, 2020	Tocilizumab	N/R	
Rossotti, 2020	Tocilizumab	infectious complication in 32.4%	
Ruiz-Antoran, 2020	Tocilizumab	32.6% in treated vs. 30.3% in control had increase in liver enzymes. Bacteraemia in 1 patient (0.4%)	
Somers, 2020	Tocilizumab	higher rate of superinfection in treated group (54% vs 26%; p<0.001)	
Tian, 2020	Tocilizumab	Deranged LFTs in 14% of tocilizumab and 14% of control group	
Tsai, 2020	Tocilizumab	N/R	
* Wadud, 2020	Tocilizumab	N/R	
Zhe ng, 2020	Tocilizumab	N/R	

Table 2 – Treatment related adverse events. Adverse events for drug under study reported. Adverse events for control population reported where applicable. * non peer-reviewed preprint study





Author	Year			GenOR (95% CI)	% We
Retrospective					
Kewan	2020 -	•		0.83 (0.69, 1.01)	12.
Potere	2020		•	1.94 (1.18, 3.19)	7.4
Somers	2020	+		1.48 (1.39, 1.58)	13.
Rodriguez-Bano	2020	٠		1.17 (1.14, 1.20)	13.
Capra	2020			2.29 (2.00, 2.62)	13.
Hill	2020			1.09 (0.98, 1.22)	13.
Zheng	2020	+		0.84 (0.80, 0.89)	13.
Eimer	2020			2.25 (1.79, 2.83)	11.
Subtotal (I-square	ed = 98.0%, p = 0.000)	\diamond	•	1.34 (1.10, 1.64)	100
Prospective					
Albertini	2020	_ _		0.99 (0.80, 1.23)	11.
#Hermine	2020	-		1.18 (1.10, 1.27)	27.
#Salvarani	2020	+		0.97 (0.90, 1.05)	27.
#*Rosas	2020	•		1.15 (1.13, 1.18)	33.
Subtotal (I-square	ed = 84.3%, p = 0.000)	\diamond		1.09 (0.99, 1.19)	100
NOTE: Weights are	e from random effects an	alysis			
	I .5	1		1 4	
	Favours C	ontrol Favou	rs Tocilizumab		



Here we are preserved in the set of the ${\rm M}^{\rm element}$

A

аb

Author	Year		aHR (95% CI)	% Wei
Retrospective				
*Martinez-Sanz	2020	+	1.53 (1.20, 1.96)	7.39
*Ramaswamy	2020 —	•	0.25 (0.07, 0.90)	2.94
Ruiz-Antoran	2020	+	0.74 (0.62, 0.89)	7.59
Guaraldi	2020 -	•	0.38 (0.17, 0.83)	4.77
Rodriguez-Bano	2020		0.12 (0.02, 0.56)	2.04
Biran	2020	-	0.64 (0.47, 0.87)	7.15
Gupta	2020	+	0.71 (0.56, 0.92)	7.38
Hill	2020		0.57 (0.21, 1.52)	3.91
Rossi	2020		0.42 (0.22, 0.82)	5.43
Somers	2020		0.55 (0.33, 0.90)	6.23
Canziani	2020		0.82 (0.42, 1.58)	5.41
De Rossi	2020		0.06 (0.02, 0.19)	3.41
Eimer	2020		0.52 (0.19, 1.39)	3.89
lp	2020	+	0.76 (0.57, 1.00)	7.25
Gokhale	2020		0.62 (0.38, 0.99)	6.35
Lewis	2020	•	0.24 (0.18, 0.33)	7.17
Narain	2020		0.79 (0.47, 1.32)	6.16
Tian	2020		0.47 (0.25, 0.90)	5.52
Subtotal (I-squar	ed = 85.9%, p = 0.000)	\diamond	0.53 (0.41, 0.71)	100
Prospective				
#Hermine	2020		0.92 (0.33, 2.53)	20.2
Roumier	2020		0.68 (0.31, 1.75)	28.0
#Stone	2020		1.52 (0.41, 5.61)	12.2
Mikulska	2020		0.48 (0.23, 0.99)	39.4
Subtotal (I-squar	ed = 0.0%, p = 0.448)	\diamond	0.70 (0.44, 1.10)	100
NOTE: Weights a	re from random effects a	analysis		
	1		1	
	.01	1	10	

-					
Retrospective				4.00	
Martinez-Sanz	2020	-	1.89 (1.44, 2.50)	4.82	260
Patel	2020		0.80 (0.37, 1.72)	2.78	42/
*Ramaswamy	2020		1.14 (0.33, 3.92)	1.58	21/
Capra	2020 -	-	0.07 (0.02, 0.28)	1.27	62/
Guaraldi	2020		0.31 (0.16, 0.60)	3.12	179
Kewan	2020	-	1.23 (0.22, 6.76)	0.96	28/
Zheng	2020		■ 8.71 (1.13, 67.32)	0.70	92/
Ruiz-Antoran	2020	+	0.53 (0.38, 0.74)	4.62	268
Rodriguez-Bano	2020		0.19 (0.05, 0.77)	1.31	88/-
Biran	2020	•	0.80 (0.68, 0.93)	5.20	210
Gupta	2020	•	0.71 (0.61, 0.83)	5.21	433
Hill	2020		0.63 (0.31, 1.28)	2.98	43/
Nasa	2020		0.16 (0.04, 0.61)	1.40	22/
Somers	2020		0.49 (0.28, 0.85)	3.61	78/
Canziani	2020		0.71 (0.42, 1.19)	3.79	64/
De Rossi	2020		0.16 (0.07, 0.33)	2.85	90/
Eimer	2020		0.71 (0.27, 1.91)	2.12	22/
Fisher	2020		0.72 (0.42, 1.24)	3.68	45/
Rosas, J.	2020		0.57 (0.19, 1.68)	1.87	20/3
Gokhale	2020	+	0.70 (0.53, 0.94)	4.78	70/
Galvan-Roman	2020		1.33 (0.70, 2.51)	3.28	58/
Guisado-Vasco	2020		1.63 (1.21, 2.20)	4.73	132
Kimmig	2020	-	1.82 (0.96, 3.47)	3.26	54/
Klopfenstein	2020	-	0.52 (0.22, 1.23)	2.47	20/-
Lewis	2020	•	0.69 (0.58, 0.82)	5.17	497
Pettit	2020	-	1.71 (1.03, 2.83)	3.84	74/
Rojas-Marte	2020	· · · · ·	0.79 (0.60, 1.05)	4.80	96/
Roomi	2020		2.08 (0.85, 5.05)	2.39	32/
Tian	2020		0.67 (0.39, 1.13)	3.75	65/
Tsai	2020	-	1.00 (0.57, 1.75)	3.61	66/
*Wadud	2020	-	0.74 (0.47, 1.17)	4.05	44/
	a = 80.3%, p = 0.000)	ă	0.76 (0.64, 0.92)	100.00	
	= = = = = = = = = = = = = = = = = = =		00 (0.0.1, 0.02)	100.00	
Prospective					
Albertini	2020		1.01 (0.07, 15.25)	0.30	22/
*Carvalho	2020		 1.03 (0.31, 3.43) 	1.52	29/
#Hermine	2020		1.24 (0.44, 3.49)	2.04	63/
Perrone	2020		0.78 (0.58, 1.05)	25.33	708
#Salvarani	2020		1.05 (0.07, 16.41)	0.29	60/
*#Rosas.I.	2020		0.87 (0.58, 1.33)	12.53	294
Roumier	2020		 1.15 (0.38, 3.52) 	1.75	49/
#Salama	2020		1.22 (0.62, 2.38)	4.84	249
#Stone	2020		1.44 (0.40, 5.17)	1.34	156
Mikulska	2020		0.57 (0.21, 1.55)	2.16	29/
*#Gordon	2020		0.57 (0.21, 1.55)	47.90	350
Subtotal (I-squared		× 1		100.00	350
		V	0.83 (0.72, 0.96)	100.00	
NOTE: Weights are	from random effects a	analysis	_		
Factor 2					
	.01	1	10 20		